Sonoma Pharmaceuticals (NASDAQ:SNOA) Stock Price Crosses Above 200 Day Moving Average – Here’s Why

Sonoma Pharmaceuticals, Inc. (NASDAQ:SNOA)’s stock price passed above its 200-day moving average during trading on Thursday . The stock has a 200-day moving average of $2.29 and traded as high as $2.85. Sonoma Pharmaceuticals shares last traded at $2.66, with a volume of 151,920 shares changing hands.

Sonoma Pharmaceuticals Price Performance

The business has a 50-day moving average of $2.70 and a 200-day moving average of $2.31. The firm has a market cap of $3.60 million, a price-to-earnings ratio of -0.54 and a beta of 1.41.

Sonoma Pharmaceuticals (NASDAQ:SNOA) last released its earnings results on Thursday, November 7th. The company reported ($0.59) earnings per share (EPS) for the quarter. The company had revenue of $3.58 million during the quarter. Sonoma Pharmaceuticals had a negative net margin of 27.21% and a negative return on equity of 59.58%. As a group, equities analysts anticipate that Sonoma Pharmaceuticals, Inc. will post -4 EPS for the current fiscal year.

Institutional Trading of Sonoma Pharmaceuticals

A hedge fund recently bought a new stake in Sonoma Pharmaceuticals stock. Ground Swell Capital LLC bought a new stake in Sonoma Pharmaceuticals, Inc. (NASDAQ:SNOA) during the third quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund bought 10,400 shares of the company’s stock, valued at approximately $32,000. Ground Swell Capital LLC owned about 1.08% of Sonoma Pharmaceuticals as of its most recent filing with the Securities and Exchange Commission (SEC). 1.95% of the stock is currently owned by hedge funds and other institutional investors.

Sonoma Pharmaceuticals Company Profile

Sonoma Pharmaceuticals, Inc, develops and produces stabilized hypochlorous acid (HOCl) products for wound care, animal health care, eye care, oral care, and dermatological conditions in the United States, Latin America, Europe, Asia, and internationally. The company offers Regenacyn, a prescription scar gel; Pediacyn, a pediatric dermatology and wound care product for over-the-counter (OTC) use; Epicyn, an Antimicrobial Facial Cleanser; Levicyn, an HOCl based prescription and OTC product to use and relieve skin irritations, lacerations, abrasions, and burns; Celacyn, a scar management gel; and SebuDerm to manage and relieve the burning, itching, erythema, scaling, and pain associated with seborrhea and seborrheic dermatitis.